William Blair analyst Adam Klauber maintained a Buy rating on Baldwin Insurance Group (BWIN – Research Report) today. The company’s shares ...

In a report released today, Brian Drab from William Blair maintained a Buy rating on Novanta (NOVT – Research Report). The company’s shares ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Parsons (NYSE:PSN) from Outperform to Market Perform. Analyst Price Forecast Suggests 97.12% Upside As of February ...

The new fund will invest in a niche subset of emerging markets that are 'more challenging for investors to access' ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...